SEVENTY SEVEN ENER COM USD0.01 (SVNT)

26.00
0.00 (0.00)
OTC
Prev Close 26.00
Open 25.60
Day Low/High 25.25 / 26.00
52 Wk Low/High 14.75 / 26.50
Volume 1.77K
Exchange OTC
Shares Outstanding 22.28B
Market Cap 562.58M
Div & Yield N.A. (N.A)

Latest News

Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks To Conduct Auction And Sale Under Section 363

Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks To Conduct Auction And Sale Under Section 363

Enters into "Stalking Horse" Sale Agreement with US WorldMeds, LLC

Interesting SVNT Put For November 16th

Interesting SVNT Put For November 16th

Investors in Savient Pharmaceuticals Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVNT options chain for the new November 16th contracts and identified the following put contract of particular interest.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

5 Biotech Stocks Under $10 Making Big Moves

5 Biotech Stocks Under $10 Making Big Moves

Keep these biotech stocks on your radar.

5 Names Seeing Bullish Flow

5 Names Seeing Bullish Flow

Henry Schwartz of Trade Alert identified five stocks seeing bullish options activity.

SVNT July Options Begin Trading

SVNT July Options Begin Trading

Investors in Savient Pharmaceuticals Inc saw new options begin trading today, for the July expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVNT options chain for the new July contracts and identified the following put contract of particular interest.

Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization For The Treatment Of Certain Patients With Chronic Tophaceous Gout

Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization For The Treatment Of Certain Patients With Chronic Tophaceous Gout

- First approved therapy in the European Union to address a significant unmet medical need for patients with chronic tophaceous gout

Arena Pharmaceuticals And 6 More Stocks To Watch

Arena Pharmaceuticals And 6 More Stocks To Watch

Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]

Savient Receives Positive CHMP Opinion For KRYSTEXXA® Approval In The EU

Savient Receives Positive CHMP Opinion For KRYSTEXXA® Approval In The EU

If Granted a Marketing Authorization, KRYSTEXXA Will Address a Significant Unmet Need for Certain Patients with Refractory Chronic Gout in the European Union

Lessons From Biotech's Best Third Quarter Stocks

Lessons From Biotech's Best Third Quarter Stocks

The biotech bubble grew in the third quarter, resulting in outsized gains for some unworthy stocks

Savient Bulls Come Back for More

Savient Bulls Come Back for More

Buyers jump into Savient calls.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Savient Pharmaceuticals Completes Financing And Debt Restructuring Transactions

Savient Pharmaceuticals Completes Financing And Debt Restructuring Transactions

Raises $44 Million in Net Proceeds and Extends Maturity on Significant Portion of its Debt

Juicy Details From Tang Capital's Lawsuit Against Savient Pharma

Juicy Details From Tang Capital's Lawsuit Against Savient Pharma

Hedge fund rips into Savient management and demands company liquidate remaining assets.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

10 Stocks That Could Rise in Market Decline

10 Stocks That Could Rise in Market Decline

Investors have heavily discounted these high-quality companies.

Savient Stock Hits New 52-Week Low (SVNT)

Savient Stock Hits New 52-Week Low (SVNT)

Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Friday as it is currently trading at $1.89, below its previous 52-week low of $1.92 with 735,750 shares traded as of 12:20 p.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Savient Stock Hits New 52-Week Low (SVNT)

Savient Stock Hits New 52-Week Low (SVNT)

Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Tuesday as it is currently trading at $2.02, below its previous 52-week low of $2.04 with 391,443 shares traded as of 10:45 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Savient Stock Gaps Down On Today's Open (SVNT)

Savient Stock Gaps Down On Today's Open (SVNT)

Shares of Savient Pharmaceuticals (Nasdaq:SVNT) were gapping down Wednesday morning with an open price 11.9% lower than Tuesday's closing price. The stock closed at $2.53 yesterday and opened today's trading at $2.23.

Savient Stock Hits New 52-Week Low (SVNT)

Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Thursday as it is currently trading at $2.20, below its previous 52-week low of $2.21 with 160,582 shares traded as of 11:20 a.m. ET. Average volume has been 1.7 million shares over the past 30 days.

Savient Stock Hits New 52-Week Low (SVNT)

Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Monday as it is currently trading at $2.26, below its previous 52-week low of $2.27 with 1.5 million shares traded as of 2:56 p.m. ET. Average volume has been 1.7 million shares over the past 30 days.